front of CELS building
News and Announcements

Replicate Bioscience Initiates a Phase 1 Trial of its Next-Generation srRNA Vaccine

Jacqueline Lim Posy, Molecular Biology BS ’06 MS ’08, was part of the research team that developed the novel vaccine technology going into trials

Posted in: Biology, In The Media, Our Alumni

Replicate Biosciences employee and alum Jacqueline Lim Posy

Replicate Bioscience, a clinical-stage company pioneering its novel self-replicating RNA (srRNA) technology to overcome the limitations of current mRNA modalities and expand use of RNA treatments to infectious disease, oncology, and autoimmune disease, today announced dosing of the first participant in a Phase 1 trial of its RBI-4000 vaccine for the prevention of rabies. The trial, which marks the first time a human has been dosed with Replicate’s next generation srRNA technology, will serve as a benchmark for utility in this indication and other complex infectious diseases and provide foundational insights to inform future clinical trials, most notably in oncology and autoimmune disease.

Jacqueline was so enthusiastic regarding her work with an RNA virus in my lab at Montclair. It is so exciting that this beginning led her to be a part of a team that is making such a significant contribution to self-replicating RNA technology.

Dr. Sandra Adams regarding Jacqueline’s time as a student

Read the Full Press Release